April 1, 2024 - Painslibrary

G created for use for the therapy of T2DM as

Chemexpress April 1, 2024 0 Comments

G created for use for the therapy of T2DM as monotherapy, and in mixture with existing therapies which includes metformin. Within this study, no impact of remogliflozin etabonate on metformin…

G created for use for the therapy of T2DM as

You Missed

2-chloro-N-[4-ethoxy-3-(piperidin-1-ylsulfonyl)phenyl]acetamide (CAS 879319-13-8)

2-chloro-N-[3-cyano-1-(2-furylmethyl)-4,5-dimethyl-1H-pyrrol-2-yl]acetamide

2-chloro-N-[2-(dimethylamino)-5-(piperidin-1-ylsulfonyl)phenyl]acetamide

2-chloro-N-(1-cyclopropylethyl)acetamide